Endoscopic Ultrasound in Diagnosing Cancer in Patients With Localized Stomach Cancer or Esophageal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00629863|
Recruitment Status : Completed
First Posted : March 6, 2008
Last Update Posted : August 7, 2013
RATIONALE: Diagnostic procedures, such as endoscopic ultrasound, may help doctors learn the extent of stomach cancer or esophageal cancer.
PURPOSE: This randomized clinical trial is studying how well endoscopic ultrasound works in diagnosing cancer in patients with localized stomach cancer or esophageal cancer.
|Condition or disease||Intervention/treatment||Phase|
|Esophageal Cancer Gastric Cancer||Drug: cisplatin Drug: fluorouracil Other: questionnaire administration Procedure: diagnostic endoscopic procedure Procedure: neoadjuvant therapy Procedure: quality-of-life assessment Procedure: therapeutic conventional surgery Procedure: therapeutic endoscopic surgery Procedure: ultrasound imaging Radiation: radiation therapy Radiation: radioisotope therapy||Not Applicable|
- To determine the additional effect of endoscopic ultrasound (EUS) staging compared with a standard staging algorithm on the selection of treatment in patients with gastric or esophageal cancer (GOC), including the numbers of patients treated surgically, with multimodality therapy, or with non-surgical means.
- To estimate the effect of EUS staging on the outcome of care of these patients.
- To assess the cost-effectiveness of EUS by comparing improvements in patient outcomes with the additional costs of the procedure.
- To estimate the proportion of patients with GOC who will benefit from EUS and therefore to determine the need for EUS facilities within a population.
OUTLINE: This is a multicenter study. Patients are stratified according to tumor location (gastric vs esophageal vs gastroesophageal junction) and participating center.
All patients undergo standard staging methods. Patients with localized tumors are randomized to undergo either endoscopic ultrasound (EUS) or no further staging. Both groups receive treatment as follows, depending on the type of tumor:
- Mucosal tumors: Patients undergo endoscopic mucosal resection and argon-beam ablation of the surrounding mucosa.
- Resectable tumors: Patients undergo surgery and neoadjuvant chemotherapy comprising cisplatin and fluorouracil.
- Advanced localized disease without the possibility of complete resection: Patients receive chemoradiotherapy or chemotherapy alone depending upon the site. Patients with gastric cancer may undergo palliative surgery.
Quality of life is assessed at 1, 3, 6, 12, 18, and 24 months using questionnaires, including the EuroQol EQ-5D, the EORTC core module QLQ-C30, the EORTC esophageal module QLQ-OES24, and the EORTC gastric module QLQ-STO22.
After completion of study treatment, patients are followed every 3 months for a minimum of 1 year.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||700 participants|
|Official Title:||Cancer of the Oesophagus or Gastricus: New Assessment of the Technology of Endosonography COGNATE|
|Study Start Date :||September 2004|
|Actual Primary Completion Date :||September 2009|
|Actual Study Completion Date :||January 2010|
- Overall survival at 12 months of patients last randomized and at 48 months of patients first randomized
- Complete resection rate
- Quality of survival in the different treatments selected on the basis of staging at 1, 3, 6, 12, 18, and 24 months by EuroQol EQ-5D, EORTC core module QLQ-C30, EORTC esophageal module QLQ-OES24, and EORTC gastric module QLQ-STO22
- Health resource utilization, including the selection of treatments and subsequent use of health service resources
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00629863
|Royal Blackburn Hospital|
|Blackburn, England, United Kingdom, BB2 3 HH|
|Gloucestershire Royal Hospital|
|Gloucester, England, United Kingdom, GL1 3NN|
|Leicester Royal Infirmary|
|Leicester, England, United Kingdom, LE1 5WW|
|North Tyneside Hospital|
|North Shields, England, United Kingdom, NE29 8NH|
|Southampton General Hospital|
|Southampton, England, United Kingdom, SO16 6YD|
|Aberdeen Royal Infirmary|
|Aberdeen, Scotland, United Kingdom, AB25 2ZN|
|Dundee, Scotland, United Kingdom, DD1 9SY|
|Royal Infirmary - Castle|
|Glasgow, Scotland, United Kingdom, G4 0SF|
|North Wales Organisation for Randomised Trials in Health|
|Bangor, Wales, United Kingdom, LL57 2PZ|
|Study Chair:||Ken Park, MD||North Wales Organisation for Randomised Trials in Health|